CR20210205A - Variantes de anticuerpo (divisional 2020-0132) - Google Patents

Variantes de anticuerpo (divisional 2020-0132)

Info

Publication number
CR20210205A
CR20210205A CR20210205A CR20210205A CR20210205A CR 20210205 A CR20210205 A CR 20210205A CR 20210205 A CR20210205 A CR 20210205A CR 20210205 A CR20210205 A CR 20210205A CR 20210205 A CR20210205 A CR 20210205A
Authority
CR
Costa Rica
Prior art keywords
antibody variants
antibodies
tnfa
bind
relates
Prior art date
Application number
CR20210205A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210205(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of CR20210205A publication Critical patent/CR20210205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos los cuales se unen al TNFa y presentan unión al FcRn modificada. Los anticuerpos de la invención tienen buenas funciones efectoras y/o propiedades farmacocinéticas.
CR20210205A 2017-09-19 2018-09-11 Variantes de anticuerpo (divisional 2020-0132) CR20210205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191989.7A EP3456738B1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074522 WO2019057564A1 (en) 2017-09-19 2018-09-11 ANTIBODY VARIANTS

Publications (1)

Publication Number Publication Date
CR20210205A true CR20210205A (es) 2021-07-27

Family

ID=59923275

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20210205A CR20210205A (es) 2017-09-19 2018-09-11 Variantes de anticuerpo (divisional 2020-0132)
CR20200132A CR20200132A (es) 2017-09-19 2018-09-11 Variantes de anticuerpo

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20200132A CR20200132A (es) 2017-09-19 2018-09-11 Variantes de anticuerpo

Country Status (26)

Country Link
US (2) US11999781B2 (es)
EP (3) EP4424707A3 (es)
JP (2) JP7240385B2 (es)
KR (2) KR102761321B1 (es)
CN (2) CN119409817A (es)
AR (1) AR113303A1 (es)
AU (2) AU2018337495B2 (es)
BR (1) BR112020005482A2 (es)
CA (1) CA3075959A1 (es)
CL (1) CL2020000721A1 (es)
CO (1) CO2020003260A2 (es)
CR (2) CR20210205A (es)
EA (1) EA202090617A1 (es)
ES (1) ES2991804T3 (es)
GE (4) GEP20237484B (es)
IL (2) IL273351B2 (es)
JO (1) JOP20200063B1 (es)
MA (1) MA50156A (es)
MX (1) MX2020002989A (es)
PH (1) PH12020500473A1 (es)
SA (1) SA520411559B1 (es)
SG (1) SG11202002220TA (es)
TW (1) TWI873084B (es)
UA (1) UA129515C2 (es)
WO (1) WO2019057564A1 (es)
ZA (1) ZA202001830B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
WO2020114616A1 (en) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2026055315A1 (en) 2024-09-05 2026-03-12 Stirx, Inc. Humanized monoclonal antibodies, methods of making and treatment of neisseria gonorrhea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
ES2359567T3 (es) * 2004-12-29 2011-05-24 Yuhan Corporation Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
RU2529951C2 (ru) * 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.
MX373485B (es) * 2014-03-26 2020-04-27 Cell Medica Switzerland Ag Miembros de unión al factor de necrosis tumoral (tnf) alfa.
CN106255704A (zh) * 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
AU2017232546B2 (en) * 2016-03-14 2024-05-02 Universitetet I Oslo Engineered immunoglobulins with altered FCRN binding
SMT202000706T1 (it) * 2016-03-17 2021-01-05 Tillotts Pharma Ag Anticorpi anti-tnf alfa e frammenti funzionali di essi

Also Published As

Publication number Publication date
JP2020534307A (ja) 2020-11-26
GEP20237484B (en) 2023-03-27
GEAP202415617A (en) 2024-06-25
BR112020005482A2 (pt) 2020-09-29
US20240343793A1 (en) 2024-10-17
IL273351A (en) 2020-05-31
EP3456738A1 (en) 2019-03-20
GEAP202215316A (en) 2022-10-25
MX2020002989A (es) 2020-07-22
KR102761321B1 (ko) 2025-02-04
TW201915021A (zh) 2019-04-16
GEP20247700B (en) 2024-11-25
EP3456738C0 (en) 2024-07-17
JOP20200063A1 (ar) 2020-03-17
AU2024287208A1 (en) 2025-02-13
PH12020500473A1 (en) 2021-01-25
EP4424707A3 (en) 2024-11-13
AR113303A1 (es) 2020-04-08
KR20250022222A (ko) 2025-02-14
IL320817A (en) 2025-07-01
AU2018337495B2 (en) 2024-10-17
JOP20200063B1 (ar) 2024-12-22
EP3456738B1 (en) 2024-07-17
KR20200053514A (ko) 2020-05-18
ZA202001830B (en) 2024-10-30
UA129515C2 (uk) 2025-05-21
CR20200132A (es) 2020-07-24
EP3684807A1 (en) 2020-07-29
CA3075959A1 (en) 2019-03-28
US11999781B2 (en) 2024-06-04
JP2023036885A (ja) 2023-03-14
MA50156A (fr) 2020-07-29
IL273351B2 (en) 2025-10-01
CN111094343B (zh) 2024-09-20
TWI873084B (zh) 2025-02-21
US20200216527A1 (en) 2020-07-09
SA520411559B1 (ar) 2024-03-19
JP7402304B2 (ja) 2023-12-20
ES2991804T3 (es) 2024-12-04
SG11202002220TA (en) 2020-04-29
CL2020000721A1 (es) 2020-08-07
EP4424707A2 (en) 2024-09-04
CO2020003260A2 (es) 2020-04-13
CN111094343A (zh) 2020-05-01
JP7240385B2 (ja) 2023-03-15
EA202090617A1 (ru) 2020-07-27
AU2018337495A1 (en) 2020-04-09
CN119409817A (zh) 2025-02-11
WO2019057564A1 (en) 2019-03-28
IL273351B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
CY1125141T1 (el) Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d
IL283939A (en) Antibodies binding to cd3
MA51734A (fr) Anticorps se liant à gprc5d
DK3645571T3 (da) Her3-antigen-bindende molekyler
IL265321B1 (en) Cd3 binding antibodies
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
IL263840A (en) Cd3 binding antibodies
CL2018000042A1 (es) Anticuerpos de unión a tau
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
CL2018000043A1 (es) Anticuerpos de unión a tau
MX377196B (es) Proteinas de fusion de inmunoglobulina de la proteina alfa reguladora de señal (sirp-alfa).
PL3374392T3 (pl) Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
EP3752534A4 (en) GLYPICANE 3 ANTIBODIES AND THEIR CONJUGATES
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
MA49289A (fr) Anticorps se liant à steap-1
SI4214240T1 (sl) Protitelesa anti-ccr8
EP4163299C0 (en) MODIFIED IGG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
EP3660155A4 (en) ANTI-CD147 ANTIBODY
EP3615678C0 (en) ANTIBODY SELECTION METHOD
EP3626745A4 (en) RECOMBINANT BISPECIFIC ANTIBODY
CY1124244T1 (el) Παραλλαγματα αντισωματος
EP3794039A4 (en) PD-1 BINDING ANTIBODIES AND USE
JP2016525099A5 (ja) 免疫グロブリンＦｃ断片のＦｃＲｎに対する結合親和力が維持される免疫グロブリンＦｃ結合体
CO2020003260A2 (es) Variantes de anticuerpo
IL310245A (en) Anti-hla-g antibodies